memantine has been researched along with Brain Neoplasms in 32 studies
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma." | 9.30 | Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. ( Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW, 2019) |
| "To investigate the effects of metformin, dichloroacetate (DCA), and memantine on T98G and U87-MG human glioblastoma (GBM) cells to target tumor cell metabolism in a multi-directional manner." | 8.02 | Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM). ( Albayrak, G; Dere, UA; Emmez, H; Konac, E, 2021) |
| "Riluzole and memantine can be safely and effectively delivered intracranially via polymer in rat glioma models." | 7.80 | Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. ( Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K, 2014) |
| " For this purpose, we measured the modulation of GDNF release in C6 glioma cell cultures treated for 24 h with amantadine and memantine." | 7.73 | Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. ( Caumont, AS; Hermans, E; Octave, JN, 2006) |
| "Memantine was withheld while dexamethasone, valproate, and morphine were continued for headache." | 5.91 | Life-threatening altered mental status secondary to memantine in an adolescent undergoing cranial radiotherapy for medulloblastoma. ( Croy, C; Kim, KN; Kotch, C; LaRiviere, M; Lustig, RA; Shah, YB, 2023) |
| "Glioblastoma is one of the most aggressive malignant primary brain cancer in adults." | 5.46 | Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma. ( Cacciatore, I; Ciulla, M; Di Stefano, A; Eusepi, P; Fornasari, E; Marinelli, L; Ozdemir, O; Tatar, A; Turkez, H, 2017) |
| "Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma." | 5.30 | Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. ( Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW, 2019) |
| " Studies in early radiotherapy treatment phase (five studies) Pharmacological studies in the "early radiotherapy treatment phase" were designed to prevent or ameliorate cognitive deficits and included drugs used in dementia (memantine) and fatigue (d-threo-methylphenidate hydrochloride)." | 5.22 | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. ( Brown, PD; Day, J; Gehring, K; Grosshans, D; Kirkman, MA; Li, J; Taphoorn, M; Zienius, K, 2022) |
| "To investigate the effects of metformin, dichloroacetate (DCA), and memantine on T98G and U87-MG human glioblastoma (GBM) cells to target tumor cell metabolism in a multi-directional manner." | 4.02 | Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM). ( Albayrak, G; Dere, UA; Emmez, H; Konac, E, 2021) |
| "Riluzole and memantine can be safely and effectively delivered intracranially via polymer in rat glioma models." | 3.80 | Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. ( Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K, 2014) |
| " For this purpose, we measured the modulation of GDNF release in C6 glioma cell cultures treated for 24 h with amantadine and memantine." | 3.73 | Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. ( Caumont, AS; Hermans, E; Octave, JN, 2006) |
| "Adult patients with brain metastases were randomized to HA-WBRT + memantine or WBRT + memantine." | 3.30 | Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. ( Armstrong, TS; Baschnagel, AM; Benzinger, TLS; Bovi, JA; Brown, PD; Deshmukh, S; Gilbert, MR; Gondi, V; Kachnic, LA; Kaufman, I; Konski, A; Kundapur, V; Mehta, MP; Roberge, D; Robinson, CG; Shah, S; Tome, WA; Usuki, KY; Wefel, JS, 2023) |
| "The management of patients with breast cancer and brain metastases (BMs) is exquisitely multidisciplinary." | 3.01 | Multidisciplinary Management of Brain Metastasis from Breast Cancer. ( Aizer, AA; Lin, NU; Trapani, D, 2023) |
| "Memantine was well tolerated and had a toxicity profile very similar to placebo." | 2.78 | Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. ( Bentzen, SM; Brown, PD; Choucair, A; Fox, S; Kavadi, V; Khuntia, D; Laack, NN; Mehta, MP; Meyers, C; Pugh, S; Roberge, D; Suh, JH; Watkins-Bruner, D; Wefel, JS, 2013) |
| "Memantine has consistently shown promise in both in-vitro and in-vivo studies as a neuroprotective agent that may improve cognitive outcomes in patients undergoing whole brain radiotherapy." | 2.61 | Preservation of cognitive function following whole brain radiotherapy in patients with brain metastases: Complications, treatments, and the emerging role of memantine. ( Lynch, M, 2019) |
| "Many patients with brain cancer experience cognitive problems." | 2.61 | Interventions for cognitive problems in adults with brain cancer: A narrative review. ( Gehring, K; Klaver, KM; Schagen, SB; Sitskoorn, MM; van Lonkhuizen, PJC; Wefel, JS, 2019) |
| "Patients with brain tumors remain at risk for infections from the perioperative period through many months after treatment, and steroids may mask signs of infection." | 2.52 | Medical management of patients with brain tumors. ( Pruitt, AA, 2015) |
| "Memantine was withheld while dexamethasone, valproate, and morphine were continued for headache." | 1.91 | Life-threatening altered mental status secondary to memantine in an adolescent undergoing cranial radiotherapy for medulloblastoma. ( Croy, C; Kim, KN; Kotch, C; LaRiviere, M; Lustig, RA; Shah, YB, 2023) |
| "Atrial myxomas are generally considered benign neoplasms." | 1.51 | Somatic PRKAR1A mutation in sporadic atrial myxoma with cerebral parenchymal metastases: a case report. ( Adams, J; Baehring, JM; Canosa, S; Huttner, A; Kimbrough, T; Madri, JA; Roque, A; Sklar, J; Traner, C, 2019) |
| "Glioblastoma is one of the most aggressive malignant primary brain cancer in adults." | 1.46 | Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma. ( Cacciatore, I; Ciulla, M; Di Stefano, A; Eusepi, P; Fornasari, E; Marinelli, L; Ozdemir, O; Tatar, A; Turkez, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.25) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 16 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JS | 1 |
| Kim, T | 1 |
| Kim, D | 1 |
| Jeong, YI | 1 |
| Surendran, HP | 1 |
| Narmadha, MP | 1 |
| Kalavagunta, S | 1 |
| Sasidharan, A | 1 |
| Dutta, D | 1 |
| Kim, KN | 1 |
| Shah, YB | 1 |
| Croy, C | 1 |
| Lustig, RA | 1 |
| LaRiviere, M | 1 |
| Kotch, C | 1 |
| Kirkman, MA | 3 |
| Day, J | 3 |
| Gehring, K | 4 |
| Zienius, K | 3 |
| Grosshans, D | 4 |
| Taphoorn, M | 3 |
| Li, J | 11 |
| Brown, PD | 9 |
| Trapani, D | 3 |
| Aizer, AA | 4 |
| Lin, NU | 3 |
| Gondi, V | 3 |
| Deshmukh, S | 2 |
| Wefel, JS | 4 |
| Armstrong, TS | 2 |
| Tome, WA | 2 |
| Gilbert, MR | 3 |
| Konski, A | 2 |
| Robinson, CG | 1 |
| Bovi, JA | 2 |
| Benzinger, TLS | 2 |
| Roberge, D | 4 |
| Kundapur, V | 2 |
| Kaufman, I | 1 |
| Shah, S | 2 |
| Usuki, KY | 1 |
| Baschnagel, AM | 1 |
| Mehta, MP | 3 |
| Kachnic, LA | 2 |
| Roque, A | 1 |
| Kimbrough, T | 1 |
| Traner, C | 1 |
| Baehring, JM | 1 |
| Huttner, A | 1 |
| Adams, J | 1 |
| Canosa, S | 1 |
| Sklar, J | 1 |
| Madri, JA | 1 |
| Pugh, S | 2 |
| Robinson, C | 1 |
| Khuntia, D | 2 |
| Bruner, D | 1 |
| Devisetty, K | 1 |
| Usuki, K | 1 |
| Anderson, BM | 1 |
| Stea, B | 1 |
| Yoon, H | 1 |
| Laack, NN | 2 |
| Kruser, TJ | 1 |
| Chmura, SJ | 1 |
| Shi, W | 1 |
| Weiner, JP | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 6 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 4 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 4 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 4 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 6 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Li, W | 3 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 6 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 7 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 7 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 4 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 3 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 3 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 3 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 2 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 1 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Lamba, N | 1 |
| Mehanna, E | 1 |
| Kearney, RB | 1 |
| Catalano, PJ | 1 |
| Haas-Kogan, DA | 1 |
| Levy, A | 1 |
| Dhermain, F | 1 |
| Botticella, A | 1 |
| Rivera, S | 1 |
| Le Péchoux, C | 1 |
| Andratschke, N | 1 |
| Belderbos, J | 1 |
| Mayinger, M | 1 |
| Schagen, SB | 2 |
| De Ruysscher, D | 1 |
| Chun, SG | 1 |
| Klopp, AH | 1 |
| Yang, WC | 1 |
| Chen, YF | 1 |
| Yang, CC | 1 |
| Wu, PF | 1 |
| Chan, HM | 1 |
| Chen, JL | 1 |
| Chen, GY | 1 |
| Cheng, JC | 1 |
| Kuo, SH | 1 |
| Hsu, FM | 1 |
| Albayrak, G | 1 |
| Konac, E | 1 |
| Dere, UA | 1 |
| Emmez, H | 1 |
| Nepali, K | 1 |
| Hsu, TI | 1 |
| Hsieh, CM | 1 |
| Lo, WL | 1 |
| Lai, MJ | 1 |
| Hsu, KC | 1 |
| Lin, TE | 1 |
| Chuang, JY | 1 |
| Liou, JP | 1 |
| Cacciatore, I | 1 |
| Fornasari, E | 1 |
| Marinelli, L | 1 |
| Eusepi, P | 1 |
| Ciulla, M | 1 |
| Ozdemir, O | 1 |
| Tatar, A | 1 |
| Turkez, H | 1 |
| Di Stefano, A | 1 |
| Altinoz, MA | 1 |
| Elmaci, İ | 1 |
| Farrell, MJ | 1 |
| Yahya, JB | 1 |
| Degnin, C | 1 |
| Chen, Y | 1 |
| Holland, JM | 1 |
| Henderson, MA | 1 |
| Jaboin, JJ | 1 |
| Harkenrider, MM | 1 |
| Thomas, CR | 1 |
| Mitin, T | 1 |
| Lynch, M | 1 |
| Maraka, S | 1 |
| Groves, MD | 1 |
| Mammoser, AG | 1 |
| Melguizo-Gavilanes, I | 1 |
| Conrad, CA | 1 |
| Tremont-Lukats, IW | 1 |
| Loghin, ME | 1 |
| O'Brien, BJ | 1 |
| Puduvalli, VK | 1 |
| Sulman, EP | 1 |
| Hess, KR | 1 |
| Aldape, KD | 1 |
| de Groot, JF | 1 |
| Alfred Yung, WK | 1 |
| Penas-Prado, M | 1 |
| van Lonkhuizen, PJC | 1 |
| Klaver, KM | 1 |
| Sitskoorn, MM | 1 |
| Blecic, S | 1 |
| Rynkowski, M | 1 |
| De Witte, O | 1 |
| Lefranc, F | 1 |
| Meyers, C | 1 |
| Choucair, A | 1 |
| Fox, S | 1 |
| Suh, JH | 1 |
| Kavadi, V | 1 |
| Bentzen, SM | 1 |
| Watkins-Bruner, D | 1 |
| Yohay, K | 1 |
| Tyler, B | 1 |
| Weaver, KD | 1 |
| Pardo, AC | 1 |
| Gincel, D | 1 |
| Blakeley, J | 1 |
| Brem, H | 1 |
| Rothstein, JD | 1 |
| Pruitt, AA | 1 |
| Slade, AN | 1 |
| Stanic, S | 1 |
| Wong, P | 1 |
| Leppert, IR | 1 |
| Boudam, K | 1 |
| Muanza, T | 1 |
| Pike, GB | 1 |
| Chankowsky, J | 1 |
| Mihalcioiu, C | 1 |
| Caumont, AS | 1 |
| Octave, JN | 1 |
| Hermans, E | 1 |
| Takano, T | 1 |
| Lin, JH | 1 |
| Arcuino, G | 1 |
| Gao, Q | 1 |
| Nedergaard, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases[NCT02360215] | Phase 3 | 518 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase 2 Prospective Trial of Hippocampal-Sparing Stereotactic Radiosurgery Treatment of Brain Metastases Using CyberKnife[NCT05177185] | Phase 2 | 70 participants (Anticipated) | Interventional | 2022-04-01 | Not yet recruiting | ||
| Neurocognitive Outcome of Conformal Whole Brain Radiotherapy With or Without Hippocampal Avoidance for Brain Metastases: A Phase II Single Blind Randomized Trial[NCT02393131] | 70 participants (Actual) | Interventional | 2015-03-03 | Active, not recruiting | |||
| Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic[NCT05504681] | 200 participants (Anticipated) | Observational | 2021-11-03 | Recruiting | |||
| A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy[NCT00566852] | Phase 3 | 554 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions[NCT04343157] | Phase 2 | 60 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme[NCT05775458] | 50 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EQ-5D-5L is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm scale ranging from 0 for the worst imaginable health state to 100 for best imaginable health state, marked at 10-point intervals. The index score is reported here. (NCT02360215)
Timeframe: Baseline and 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| HA-WBRT + Memantine | -0.03 |
| WBRT + Memantine | -0.01 |
The EQ-5D-5L is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm scale ranging from 0 for the worst imaginable health state to 100 for best imaginable health state, marked at 10-point intervals. The index score is reported here. (NCT02360215)
Timeframe: Baseline and 2 months
| Intervention | score on a scale (Mean) |
|---|---|
| HA-WBRT + Memantine | -0.04 |
| WBRT + Memantine | -0.05 |
The EQ-5D-5L is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm scale ranging from 0 for the worst imaginable health state to 100 for best imaginable health state, marked at 10-point intervals. The index score is reported here. (NCT02360215)
Timeframe: Baseline and 4 months
| Intervention | score on a scale (Mean) |
|---|---|
| HA-WBRT + Memantine | -0.03 |
| WBRT + Memantine | -0.03 |
The EQ-5D-5L is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm scale ranging from 0 for the worst imaginable health state to 100 for best imaginable health state, marked at 10-point intervals. The index score is reported here. (NCT02360215)
Timeframe: Baseline and 6 months
| Intervention | score on a scale (Mean) |
|---|---|
| HA-WBRT + Memantine | -0.03 |
| WBRT + Memantin | -0.03 |
The EQ-5D-5L is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm scale ranging from 0 for the worst imaginable health state to 100 for best imaginable health state, marked at 10-point intervals. The VAS score is reported here. (NCT02360215)
Timeframe: Baseline and 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| HA-WBRT + Memantine | 2.86 |
| WBRT + Memantine | 2.42 |
The EQ-5D-5L is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm scale ranging from 0 for the worst imaginable health state to 100 for best imaginable health state, marked at 10-point intervals. The VAS score is reported here. (NCT02360215)
Timeframe: Baseline and 2 months
| Intervention | score on a scale (Mean) |
|---|---|
| HA-WBRT + Memantine | -5.64 |
| WBRT + Memantine | -1.41 |
The EQ-5D-5L is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm scale ranging from 0 for the worst imaginable health state to 100 for best imaginable health state, marked at 10-point intervals. The VAS score is reported here. (NCT02360215)
Timeframe: Baseline and 4 months
| Intervention | score on a scale (Mean) |
|---|---|
| HA-WBRT + Memantine | -1.35 |
| WBRT + Memantine | -2.98 |
The EQ-5D-5L is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm scale ranging from 0 for the worst imaginable health state to 100 for best imaginable health state, marked at 10-point intervals. The VAS score is reported here. (NCT02360215)
Timeframe: Baseline and 6 months
| Intervention | score on a scale (Mean) |
|---|---|
| HA-WBRT + Memantine | 3.97 |
| WBRT + Memantine | 3.49 |
Intracranial progression-free survival time is defined as time from registration/randomization to the date of progression in the brain or death from any cause. Intracranial progression-free survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Analysis was planned to occur after 233 primary endpoint events (neurocognitive failure) were reported. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Six-month rates are provided. (NCT02360215)
Timeframe: From randomization to last follow-up. Analysis was planned to occur after 233 events were reported. Maximum follow-up was 15.6 months.
| Intervention | percentage of participants (Number) |
|---|---|
| HA-WBRT + Memantine | 43.9 |
| WBRT + Memantine | 44.8 |
. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. (NCT02360215)
Timeframe: From randomization to last follow-up. Analysis was planned to occur after 233 events were reported. Maximum follow-up was 15.6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| HA-WBRT + Memantine | 144 |
| WBRT + Memantine | 131 |
Overall survival time is defined as time from registration/randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Analysis was planned to occur after 233 primary endpoint events (neurocognitive failure) were reported. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Six-month rates are provided. (NCT02360215)
Timeframe: From randomization to last follow-up. Maximum follow-up was 15.6 months.
| Intervention | percentage of participants (Number) |
|---|---|
| HA-WBRT + Memantine | 54.9 |
| WBRT + Memantine | 50.6 |
Neurocognitive failure is defined as the first failure, defined as a neurocognitive decline using the reliable change index (RCI) on at least one of the following assessments or parts of : Hopkins Verbal Learning Test - Revised (HVLT-R), Trail Making Test (TMT), or Controlled Oral Word Association (COWA). The HVLT-R has 3 parts that were analyzed separately for decline: Total Recall, Delayed Recall, and Delayed Recognition. The TMT has 2 parts that were analyzed separately: Part A and Part B. Neurocognitive failure rate is estimated using the cumulative incidence method. Analysis was planned to occur after 233 events were reported. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Six-month rates are provided.Analysis was planned to occur after 233 events were reported. (NCT02360215)
Timeframe: From randomization to last follow-up. Maximum follow-up was 15.6 months.
| Intervention | percentage of participants (Number) |
|---|---|
| HA-WBRT + Memantine | 68.2 |
| WBRT + Memantine | 59.3 |
Clinical Trial Battery Composite score is the arithmetic mean of the HVLT-R (Free Recall, Delayed Recall, Delayed Recognition), TMTA, TMTB, and COWA scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function.Change is calculated as baseline score subtracted from post-baseline score. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | -1.09 | -0.81 | -0.44 | -0.98 |
| WBRT + Memantine | -0.87 | -0.27 | -0.21 | -0.61 |
The COWA is a verbal fluency test that measures spontaneous production of words belonging to the same category or beginning with some designated letter. Patients are given 1 minute to name as many words as possible beginning with the designated letter. The procedure is then repeated for the remaining two letters. Two alternate forms of the COWA are employed to minimize practice effects. The score is the sum of the correct responses with a range of 0 to infinity. A higher score indicates better functioning. Scores are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. Change is calculated as baseline score subtracted from post-baseline score. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | -0.28 | -0.06 | -0.15 | -0.44 |
| WBRT + Memantine | -0.29 | -0.08 | -0.11 | -0.21 |
The HVLT-R assesses verbal learning and memory. The test involves memorizing a list of 12 nouns for 3 consecutive trials (Total Recall), recalling the 12 targets after a 20-minute delay (Delayed Recall), and then identifying the 12 targets from a list of semantically related or unrelated items (delayed recognition). Raw scores are derived for total recall (sum of the number of targets correctly recalled), delayed recall (sum of the number of targets correctly recalled), and a delayed recognition discrimination index (sum of targets incorrectly identified subtracted from the sum of the number of targets correctly identified). The range of scores for total recall is 0 to 36, for delayed recall is 0 to 12, and -12 to 12 for recognition. A higher score indicates better functioning. Scores are standardized, adjusting for age, education, and gender as necessary, such that mean 0 and standard deviation is 1. Change is calculated as baseline score subtracted from post-baseline score. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | -0.75 | -0.88 | -0.54 | -0.89 |
| WBRT + Memantine | -0.73 | -0.68 | -0.30 | -0.87 |
The HVLT-R assesses verbal learning and memory. The test involves memorizing a list of 12 nouns for 3 consecutive trials (Total Recall), recalling the 12 targets after a 20-minute delay (Delayed Recall), and then identifying the 12 targets from a list of semantically related or unrelated items (delayed recognition). Raw scores are derived for total recall (sum of the number of targets correctly recalled), delayed recall (sum of the number of targets correctly recalled), and a delayed recognition discrimination index (sum of targets incorrectly identified subtracted from the sum of the number of targets correctly identified). The range of scores for total recall is 0 to 36, for delayed recall is 0 to 12, and -12 to 12 for recognition. A higher score indicates better functioning. Scores are standardized by expressing the deviation from the mean score of the group in units of standard deviation. Change is calculated as baseline score subtracted from post-baseline score. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | -0.69 | -0.11 | -0.55 | -0.48 |
| WBRT + Memantine | -0.70 | -0.12 | -0.06 | -0.30 |
The HVLT-R assesses verbal learning and memory. The test involves memorizing a list of 12 nouns for 3 consecutive trials (Total Recall), recalling the 12 targets after a 20-minute delay (Delayed Recall), and then identifying the 12 targets from a list of semantically related or unrelated items (delayed recognition). Raw scores are derived for total recall (sum of the number of targets correctly recalled), delayed recall (sum of the number of targets correctly recalled), and a delayed recognition discrimination index (sum of targets incorrectly identified subtracted from the sum of the number of targets correctly identified). The range of scores for total recall is 0 to 36, for delayed recall is 0 to 12, and -12 to 12 for recognition. A higher score indicates better functioning. Scores are standardized, adjusting for age, education, and gender as necessary, such that mean 0 and standard deviation is 1. Change is calculated as baseline score subtracted from post-baseline score. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | -0.63 | -0.68 | -0.34 | -0.55 |
| WBRT + Memantine | -0.47 | -0.36 | -0.06 | -0.34 |
The TMT is a neuropsychological test of visual attention and task switching that can provide information about visual search speed, scanning, speed of processing, mental flexibility, and executive functioning. Subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. There are two parts to the test: in the first (Part A), the targets are all numbers (1, 2, 3, etc.) and the test taker needs to connect them in sequential order; in the second part (Part B), the subject alternates between numbers and letters (1, A, 2, B, etc.). The score is the amount of time, in seconds, that it takes the patient to complete each maze. The range for Part A is 0 to 180 (3 minutes) and for Part B is 0 to 300 (5 minutes). Lower scores indicate better functioning. Scores are standardized, adjusting for age, education, gender as needed, so that mean is 0 and standard deviation is 1. Change is calculated as baseline score subtracted from post-baseline score. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | -1.42 | -0.28 | -2.09 | -1.28 |
| WBRT + Memantine | -1.31 | 0.03 | 0.17 | -0.70 |
The TMT is a neuropsychological test of visual attention and task switching that can provide information about visual search speed, scanning, speed of processing, mental flexibility, and executive functioning. Subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. There are two parts to the test: in the first (Part A), the targets are all numbers (1, 2, 3, etc.) and the test taker needs to connect them in sequential order; in the second part (Part B), the subject alternates between numbers and letters (1, A, 2, B, etc.). The score is the amount of time, in seconds, that it takes the patient to complete each maze. The range for Part A is 0 to 180 (3 minutes) and for Part B is 0 to 300 (5 minutes). A lower score indicates better functioning. Scores are standardized by expressing the deviation from the mean score of the group in units of standard deviation. Change is calculated as baseline score subtracted from post-baseline score. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | -2.86 | -3.38 | -0.47 | -2.49 |
| WBRT + Memantine | -2.27 | -0.89 | -1.06 | -1.44 |
The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score (Cognitive Factor) is the average of the subscale items, given that a specified minimum numbers of items were completed. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | 0.45 | 0.52 | 0.57 | 1.04 |
| WBRT + Memantine | 0.50 | 0.32 | 0.01 | 0.50 |
The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score (Interference) is the average of the subscale items, given that a specified minimum numbers of items were completed. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | 0.84 | 0.35 | 0.57 | 0.64 |
| WBRT + Memantine | 1.09 | 0.51 | 0.01 | 0.14 |
The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score (Neurologic Factor) is the average of the subscale items, given that a specified minimum numbers of items were completed. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | 0.17 | 0.13 | 0.23 | 0.60 |
| WBRT + Memantine | 0.28 | 0.24 | 0.15 | 0.40 |
The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score (Symptom Severity) is the average of the subscale items, given that a specified minimum numbers of items were completed. (NCT02360215)
Timeframe: Baseline, 2, 4, 6, and 12 months
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| 2 months | 4 months | 6 months | 12 months | |
| HA-WBRT + Memantine | 0.48 | 0.29 | 0.24 | 0.53 |
| WBRT + Memantine | 0.61 | 0.36 | -0.09 | 0.09 |
The FACT-Br is a 50-question self-report questionnaire contains the following domains (scales): Physical well-being (7 questions), social/family well-being (7 questions), emotional well-being (6 questions), functional well-being (7 questions) and brain cancer subscale which contains concerns relevant to patients with brain tumors (23 questions). Each question has a value 0-4. For some questions a higher indicates better outcome and others are the opposite. The former are summed as is, the latter are reversed in value before adding, such that each domain ranges from 0 to 4 times the number of questions in the domain, with 0 indicating worst and the highest possible value indicating best outcome. The FACT-Br total is obtained by adding all domains together if the overall question response rate is greater than 80%. Total scores on the FACT-Br range from 0 to 184 with lower scores indicating declining quality of life. Change is calculated as baseline score subtracted from 24-week score. (NCT00566852)
Timeframe: Baseline and 24 weeks from start of treatment
| Intervention | units on a scale (Median) |
|---|---|
| WBRT+Memantine | 0 |
| WBRT+Placebo | 1 |
The HVLT-R consists of 3 parts. Free call has a range of 0 to 36, delayed recall has a range from 0 to 12, and delayed recognition has a range of -12 to 12. Higher scores indicating better function in all 3 parts. Standardized scores are used by calculating an average standardized z score for each part of the HVLT-R. Change is calculated by subtracting baseline value from 24-week value. Imputation methods were used to determine values for all alive patients missing the 24 week assessment. This tool is being used to measure cognitive function, specifically memory. (NCT00566852)
Timeframe: Baseline and 24 weeks from the start of drug treatment
| Intervention | units on a scale (Median) |
|---|---|
| WBRT+Memantine | 0 |
| WBRT+Placebo | -0.9 |
Disease progression is defined as the first of the following events: an increase of at least 50% for lesions less than or equal to 1cm, an increase of least 25% for lesions greater than 1cm, appearance of any new brain metastases. Failure for progression-free survival is disease progression or death. Median progression-free survival was estimated using the Kaplan-Meier method. (NCT00566852)
Timeframe: From randomization to date of progression, death or last follow-up. Analysis occurs at the same time as the primary outcome. Patients are followed until death and all follow-up collected at time of analysis is used.
| Intervention | months (Mean) |
|---|---|
| WBRT+Memantine | 4.7 |
| WBRT+Placebo | 5.5 |
Neurocognitive failure is defined as the first cognitive failure on any of the neurocognitive tests: the HVLT-R for immediate recall, delayed recognition, and delayed recall; the Controlled Oral Word Association Test (COWAT); the Trail-Making Test (TMT) Parts A and B. Cognitive failure for each test is defined as a post-treatment score that meets one of the following criteria: follow-up score is at least 2 standard deviations worse than the patient's personal baseline score or the patient's raw score change is greater than the reliable change index. The cumulative incidence approach was used to estimate the median time to neurocognitive failure to account for the competing risks of disease progression and death. (NCT00566852)
Timeframe: Baseline to 12 months from the start of drug treatment
| Intervention | years (Median) |
|---|---|
| WBRT+Memantine | 2.6 |
| WBRT+Placebo | 2.3 |
Failure for overall survival is death from any cause. Median survival was estimated using the Kaplan-Meier method. (NCT00566852)
Timeframe: From randomization to date of death or last follow-up. Analysis occurs at the same time as the primary outcome. Patients are followed until death and all follow-up collected at time of analysis is used.
| Intervention | months (Median) |
|---|---|
| WBRT+Memantine | 6.7 |
| WBRT+Placebo | 7.8 |
The HVLT-R consists of 3 parts. Free call has a range of 0 to 36, delayed recall has a range from 0 to 12, and delayed recognition has a range of -12 to 12. Higher scores indicating better function in all 3 parts. Standardized scores are used by calculating an average standardized z score for each part of the HVLT-R. Change is calculated by subtracting baseline value from the respective later time point value. Imputation methods were used to determine values for all alive patients missing the post-baseline assessments. This tool is being used to measure cognitive function, specifically memory. (NCT00566852)
Timeframe: Baseline, 8, 16, and 52 weeks from the start of drug treatment
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| 8-weeks | 16-weeks | 52-weeks | |
| WBRT+Memantine | -0.36 | 0 | 0 |
| WBRT+Placebo | -0.72 | 0 | 0 |
9 reviews available for memantine and Brain Neoplasms
| Article | Year |
|---|---|
Preservation of cognitive function after brain irradiation.
Topics: Brain; Brain Neoplasms; Cognition; Humans; Memantine; Quality of Life | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Multidisciplinary Management of Brain Metastasis from Breast Cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Memantine; Radiosurgery | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Targeting nitric oxide and NMDA receptor-associated pathways in treatment of high grade glial tumors. Hypotheses for nitro-memantine and nitrones.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Cell Proliferation; Cyclic N-Oxi | 2018 |
Preservation of cognitive function following whole brain radiotherapy in patients with brain metastases: Complications, treatments, and the emerging role of memantine.
Topics: Brain Neoplasms; Cognition; Cranial Irradiation; Humans; Memantine; Memory; Neoplasm Staging | 2019 |
Interventions for cognitive problems in adults with brain cancer: A narrative review.
Topics: Brain Neoplasms; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognition; Cognitive | 2019 |
[Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications].
Topics: Benzodiazepines; Brain Neoplasms; Cell Death; Cell Movement; Cell Proliferation; Dizocilpine Maleate | 2013 |
Medical management of patients with brain tumors.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Brain Edema; Brain Neoplasms; Cognition Disorders; Dopamin | 2015 |
7 trials available for memantine and Brain Neoplasms
| Article | Year |
|---|---|
Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001.
Topics: Adult; Brain; Brain Neoplasms; Cognition; Cranial Irradiation; Hippocampus; Humans; Memantine | 2023 |
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Topics: Antiparkinson Agents; Brain Neoplasms; Chemoradiotherapy; Cognition; Cognition Disorders; Female; Hi | 2020 |
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Topics: Antiparkinson Agents; Brain Neoplasms; Chemoradiotherapy; Cognition; Cognition Disorders; Female; Hi | 2020 |
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Topics: Antiparkinson Agents; Brain Neoplasms; Chemoradiotherapy; Cognition; Cognition Disorders; Female; Hi | 2020 |
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Topics: Antiparkinson Agents; Brain Neoplasms; Chemoradiotherapy; Cognition; Cognition Disorders; Female; Hi | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
Topics: Brain Neoplasms; Cranial Irradiation; Hippocampus; Humans; Memantine; Radiation Injuries | 2021 |
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2019 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Double-Bl | 2013 |
A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy.
Topics: Adult; Aged; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeability; Contrast Media; Cranial I | 2016 |
17 other studies available for memantine and Brain Neoplasms
| Article | Year |
|---|---|
The Effect of Oxidative Stress and Memantine-Incorporated Reactive Oxygen Species-Sensitive Nanoparticles on the Expression of
Topics: Alzheimer Disease; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; | 2021 |
Life-threatening altered mental status secondary to memantine in an adolescent undergoing cranial radiotherapy for medulloblastoma.
Topics: Adolescent; Brain Neoplasms; Cerebellar Neoplasms; Child; Cranial Irradiation; Humans; Male; Medullo | 2023 |
Somatic PRKAR1A mutation in sporadic atrial myxoma with cerebral parenchymal metastases: a case report.
Topics: Brain Neoplasms; Carney Complex; Chemoradiotherapy; Cyclic AMP-Dependent Protein Kinase RIalpha Subu | 2019 |
Neurocognitive Outcomes for Patients With Brain Metastasis in the Modern Era: Benefit of Treatment With Hippocampal Avoidance Whole-Brain Radiotherapy Plus Memantine.
Topics: Brain Neoplasms; Cranial Irradiation; Hippocampus; Humans; Memantine | 2020 |
Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study.
Topics: Aged; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Excitatory Amino Acid Antagonists; | 2020 |
Hippocampal Avoidance Whole-Brain Radiotherapy (WBRT) Versus WBRT in Patients With Brain Metastases: Were Hippocampi the Only Difference?
Topics: Brain Neoplasms; Cranial Irradiation; Hippocampus; Humans; Memantine | 2020 |
Hippocampal Avoidance and Memantine for Whole-Brain Radiotherapy: Long-Term Follow-Up Warranted.
Topics: Brain Neoplasms; Cranial Irradiation; Follow-Up Studies; Hippocampus; Humans; Memantine | 2020 |
Meeting the Burden of Proof to Justify Intensity-Modulated Radiation for Brain Metastases.
Topics: Brain; Brain Neoplasms; Hippocampus; Humans; Memantine; Radiation; Radiotherapy, Intensity-Modulated | 2020 |
Reply to S.G. Chun et al, A. Levy et al, and N. Andratschke et al.
Topics: Brain Neoplasms; Hippocampus; Humans; Medical Oncology; Memantine | 2020 |
Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM).
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dichloroacetic A | 2021 |
Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Proliferation; Dose-Respo | 2021 |
Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Antineoplastic Agents; Blood Cells; Blood-Brain Barrier; Brain N | 2017 |
Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer: Survey of US Radiation Oncologists on Current Practice Patterns.
Topics: Brain; Brain Neoplasms; Cognition Disorders; Cranial Irradiation; Humans; Lung Neoplasms; Memantine; | 2018 |
Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Excitator | 2014 |
The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases.
Topics: Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cranial Ir | 2016 |
Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells.
Topics: 5' Untranslated Regions; Amantadine; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dopa | 2006 |
Glutamate release promotes growth of malignant gliomas.
Topics: Amino Acid Transport System X-AG; Animals; Brain Neoplasms; Carrier Proteins; Cell Division; Dizocil | 2001 |